Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
about
Third-generation CD28/4-1BB chimeric antigen receptor T cells for chemotherapy relapsed or refractory acute lymphoblastic leukaemia: a non-randomised, open-label phase I trial protocol.Phase I Escalating-Dose Trial of CAR-T Therapy Targeting CEA+ Metastatic Colorectal Cancers.mRNA Cancer Vaccines.Hit-and-run programming of therapeutic cytoreagents using mRNA nanocarriers.Chimeric Antigen Receptor (CAR) Treg: A Promising Approach to Inducing Immunological Tolerance
P2860
Erratum: Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.Erratum: Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
P921
Enhancement of the in vivo persistence and antitumor efficacy of CD19 chimeric antigen receptor T cells through the delivery of modified TERT mRNA.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Enhancement of the in vivo per ...... elivery of modified TERT mRNA.
@en
type
label
Enhancement of the in vivo per ...... elivery of modified TERT mRNA.
@en
prefLabel
Enhancement of the in vivo per ...... elivery of modified TERT mRNA.
@en
P2093
P2860
P356
P1433
P1476
Enhancement of the in vivo per ...... elivery of modified TERT mRNA.
@en
P2093
Hongkui Deng
Jinhua Wen
John P Cooke
Shifeng Kan
Shixin Zhou
Yuting Wang
P2507
P2860
P2888
P356
10.1038/CELLDISC.2015.40
P577
2015-12-08T00:00:00Z